Raltegravir

Indications

Raltegravir is used in combination with other antiretroviral medications to treat human immunodeficiency virus (HIV-1) infection. It is approved for use in adults and children, including infants who meet specific weight requirements.

This medication belongs to a class of drugs called integrase inhibitors. It is never used alone; it must be taken as part of a multi-drug regimen to effectively manage the virus.

Goals of Therapy

When used as part of a complete treatment plan, raltegravir helps to:

• Decrease the amount of HIV in the blood (viral load).
• Increase the number of CD4 (T) cells, which are white blood cells that help the immune system fight infections.
• Reduce the risk of complications associated with HIV infection.

Important Considerations

While raltegravir helps control HIV, it is important to understand its limitations:

• It is not a cure for HIV or AIDS.
• It does not prevent the transmission of HIV to other people through sexual contact or exposure to blood.
• It must be taken exactly as prescribed, alongside other HIV medications, to maintain its effectiveness and prevent the virus from becoming resistant to treatment.

Mechanism of Action

Raltegravir belongs to a class of drugs known as integrase strand transfer inhibitors (INSTIs). It targets an enzyme called HIV-1 integrase, which is essential for the virus to reproduce. HIV uses this enzyme to insert its own genetic material into the DNA of human immune cells, specifically CD4 cells.

By blocking the integrase enzyme, raltegravir prevents the virus from integrating into the host cell's DNA. This interruption stops the virus from making copies of itself, which helps to:

• Decrease the amount of HIV in the blood (viral load).
• Increase the number of CD4 cells, which are white blood cells that help the immune system fight infections.

While raltegravir helps manage the infection and reduce the risk of complications, it is not a cure for HIV or AIDS. It must be used in combination with other antiretroviral medications to be effective.

Common Side Effects

Some people may experience mild side effects while taking raltegravir. These often include:

• Nausea
• Headache
• Dizziness
• Tiredness or weakness
• Diarrhea
• Stomach pain
• Difficulty falling asleep or staying asleep
• Fever

Serious Side Effects

While less common, raltegravir can cause serious or life-threatening side effects. Seek medical attention immediately for any of the following:

• Severe skin or allergic reactions: A skin rash that may be accompanied by fever, blisters, peeling, or swelling of the face, lips, and tongue.
• Liver issues: Symptoms such as yellowing of the eyes or skin (jaundice), dark urine, pale stools, or pain in the upper right stomach area.
• Muscle breakdown: Unexplained muscle pain, tenderness, or weakness, which may be signs of rhabdomyolysis.
• Mental health changes: New or worsening depression, anxiety, or suicidal thoughts.
• Immune system changes: Signs of a new or old infection, such as fever, swollen glands, or cough, which may occur as the immune system strengthens (immune reconstitution syndrome).
• Kidney problems: Changes in how much you urinate or swelling in your feet and ankles.

Seek emergency medical help if you show signs of a severe allergic reaction, such as hives or difficulty breathing.

Severe Skin and Hypersensitivity Reactions

Serious and potentially life-threatening skin reactions have been reported in patients taking raltegravir. These include Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS). Treatment is typically discontinued immediately if a rash develops along with systemic symptoms such as:

• Fever
• General malaise or extreme tiredness
• Muscle or joint aches
• Blisters or skin peeling
• Oral sores or lesions
• Swelling of the face or eyes
• Hepatitis (liver inflammation)

Immune Reconstitution Syndrome

Patients with HIV may experience immune reconstitution syndrome when starting combination antiretroviral therapy. As the immune system strengthens, it may develop an inflammatory response to hidden or lingering opportunistic infections, such as Mycobacterium avium complex, cytomegalovirus, or tuberculosis. Autoimmune disorders, such as Graves' disease, polymyositis, or Guillain-Barré syndrome, have also been reported to occur months after starting treatment.

Muscle and Liver Concerns

Myopathy and rhabdomyolysis (severe muscle breakdown) have occurred in patients using raltegravir. Caution is advised for individuals with a history of muscle disorders or those taking other medications known to cause muscle issues, such as statins. Additionally, while raltegravir is generally well-tolerated by the liver, patients with severe underlying hepatic impairment should be monitored closely.

Phenylketonuria (PKU)

The chewable tablet formulation of raltegravir contains phenylalanine. This is an important consideration for individuals with phenylketonuria, a genetic condition where the body cannot properly process this amino acid.

Drug Interactions

Certain medications can significantly affect the levels of raltegravir in the body, potentially reducing its effectiveness:

• Antacids: Antacids containing aluminum or magnesium can significantly decrease the absorption of raltegravir and should be avoided.
• Rifampin: This antibiotic can lower the concentration of raltegravir in the blood, which may require a dosage adjustment of raltegravir.

Pregnancy

Raltegravir is often prescribed during pregnancy to manage HIV-1 infection and lower the risk of transmitting the virus to the fetus. While research suggests it is generally safe, it should be used only when the benefits outweigh the potential risks. Healthcare providers may encourage enrollment in a pregnancy registry to monitor the health of both the parent and the infant.

Breastfeeding

The Centers for Disease Control and Prevention (CDC) and other health organizations generally recommend that individuals with HIV avoid breastfeeding. This recommendation is intended to prevent the transmission of HIV to the baby through breast milk. It is currently unknown if raltegravir is excreted in human breast milk, although animal studies have shown the drug can pass into milk. Parents should discuss safe infant feeding alternatives with their healthcare team.

Available Dosage Forms

Raltegravir is provided in several different oral forms to accommodate different age groups and dosing requirements:

• Film-coated tablets: These are standard tablets intended to be swallowed whole.
• Chewable tablets: These tablets can be chewed or swallowed whole and are often used for pediatric patients.
• Granules for oral suspension: This form consists of packets of powder that are mixed with water to create a liquid dose, typically used for infants and young children.

It is important to note that different formulations of raltegravir are not always interchangeable. For example, the chewable tablets and the oral suspension granules may have different dosing instructions than the standard film-coated tablets. Always use the specific form prescribed by a healthcare provider.

FDA Approval Status

Raltegravir was first approved by the U.S. Food and Drug Administration (FDA) in 2007. It is classified as an HIV-1 integrase strand transfer inhibitor.

Approved Indications

The medication is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. Its approved use extends to:

• Adult patients
• Pediatric patients weighing at least 2 kg

Regulatory Requirements

The FDA does not require a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) for raltegravir. However, the drug must be dispensed with an FDA-approved Medication Guide that outlines potential risks, including severe skin reactions and hypersensitivity. Raltegravir is not a controlled substance.

Factors Affecting Cost

The price of raltegravir can vary based on several factors:

• Formulation: This medication is available in different forms, including film-coated tablets, chewable tablets, and oral suspension. The specific form prescribed can influence the total cost.
• Generic vs. Brand Name: Generic raltegravir is available for some strengths and typically costs less than the brand-name version, Isentress.
• Insurance and Medicare: Most insurance plans and Medicare Part D cover raltegravir, but the patient's share of the cost depends on the plan's specific benefits and drug tiers.

Financial Assistance Programs

For individuals who have difficulty affording raltegravir, several options may be available:

• Manufacturer Assistance: The drug manufacturer may offer copay cards or patient assistance programs for those who qualify based on income or insurance status.
• Government Programs: Programs such as the AIDS Drug Assistance Program (ADAP) help provide HIV medications to low-income individuals who are uninsured or underinsured.